Literature DB >> 27114453

Multidimensional Proteomics Reveals a Role of UHRF2 in the Regulation of Epithelial-Mesenchymal Transition (EMT).

Mi Lai1, Lizhu Liang1, Jiwei Chen2, Naiqi Qiu2, Sai Ge3, Shuhui Ji1, Tieliu Shi2, Bei Zhen1, Mingwei Liu1, Chen Ding1, Yi Wang4, Jun Qin5.   

Abstract

UHRF1 is best known for its positive role in the maintenance of DNMT1-mediated DNA methylation and is implicated in a variety of tumor processes. In this paper, we provided evidence to demonstrate a role of UHRF2 in cell motility and invasion through the regulation of the epithelial-mesenchymal transition (EMT) process by acting as a transcriptional co-regulator of the EMT-transcription factors (TFs). We ectopically expressed UHRF2 in gastric cancer cell lines and performed multidimensional proteomics analyses. Proteome profiling analysis suggested a role of UHRF2 in repression of cell-cell adhesion; analysis of proteome-wide TF DNA binding activities revealed the up-regulation of many EMT-TFs in UHRF2-overexpressing cells. These data suggest that UHRF2 is a regulator of cell motility and the EMT program. Indeed, cell invasion experiments demonstrated that silencing of UHRF2 in aggressive cells impaired their abilities of migration and invasion in vitro Further ChIP-seq identified UHRF2 genomic binding motifs that coincide with several TF binding motifs including EMT-TFs, and the binding of UHRF2 to CDH1 promoter was validated by ChIP-qPCR. Moreover, the interactome analysis with IP-MS uncovered the interaction of UHRF2 with TFs including TCF7L2 and several protein complexes that regulate chromatin remodeling and histone modifications, suggesting that UHRF2 is a transcription co-regulator for TFs such as TCF7L2 to regulate the EMT process. Taken together, our study identified a role of UHRF2 in EMT and tumor metastasis and demonstrated an effective approach to obtain clues of UHRF2 function without prior knowledge through combining evidence from multidimensional proteomics analyses.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27114453      PMCID: PMC4937503          DOI: 10.1074/mcp.M115.057448

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  63 in total

Review 1.  Increasing role of UHRF1 in the reading and inheritance of the epigenetic code as well as in tumorogenesis.

Authors:  Christian Bronner; Mounira Krifa; Marc Mousli
Journal:  Biochem Pharmacol       Date:  2013-10-14       Impact factor: 5.858

2.  Recognition of multivalent histone states associated with heterochromatin by UHRF1 protein.

Authors:  Nataliya Nady; Alexander Lemak; John R Walker; George V Avvakumov; Michael S Kareta; Mayada Achour; Sheng Xue; Shili Duan; Abdellah Allali-Hassani; Xiaobing Zuo; Yun-Xing Wang; Christian Bronner; Frédéric Chédin; Cheryl H Arrowsmith; Sirano Dhe-Paganon
Journal:  J Biol Chem       Date:  2011-04-13       Impact factor: 5.157

Review 3.  Regulatory networks defining EMT during cancer initiation and progression.

Authors:  Bram De Craene; Geert Berx
Journal:  Nat Rev Cancer       Date:  2013-02       Impact factor: 60.716

4.  The SLUG zinc-finger protein represses E-cadherin in breast cancer.

Authors:  Karen M Hajra; David Y-S Chen; Eric R Fearon
Journal:  Cancer Res       Date:  2002-03-15       Impact factor: 12.701

Review 5.  Molecular networks that regulate cancer metastasis.

Authors:  Daniela Spano; Chantal Heck; Pasqualino De Antonellis; Gerhard Christofori; Massimo Zollo
Journal:  Semin Cancer Biol       Date:  2012-03-30       Impact factor: 15.707

Review 6.  Oncogenic roles of EMT-inducing transcription factors.

Authors:  Alain Puisieux; Thomas Brabletz; Julie Caramel
Journal:  Nat Cell Biol       Date:  2014-06       Impact factor: 28.824

7.  Structure and hemimethylated CpG binding of the SRA domain from human UHRF1.

Authors:  Chengmin Qian; Side Li; Jean Jakoncic; Lei Zeng; Martin J Walsh; Ming-Ming Zhou
Journal:  J Biol Chem       Date:  2008-10-22       Impact factor: 5.157

8.  Recognition of hemi-methylated DNA by the SRA protein UHRF1 by a base-flipping mechanism.

Authors:  Kyohei Arita; Mariko Ariyoshi; Hidehito Tochio; Yusuke Nakamura; Masahiro Shirakawa
Journal:  Nature       Date:  2008-09-03       Impact factor: 49.962

9.  Dissecting engineered cell types and enhancing cell fate conversion via CellNet.

Authors:  Samantha A Morris; Patrick Cahan; Hu Li; Anna M Zhao; Adrianna K San Roman; Ramesh A Shivdasani; James J Collins; George Q Daley
Journal:  Cell       Date:  2014-08-14       Impact factor: 41.582

10.  CellNet: network biology applied to stem cell engineering.

Authors:  Patrick Cahan; Hu Li; Samantha A Morris; Edroaldo Lummertz da Rocha; George Q Daley; James J Collins
Journal:  Cell       Date:  2014-08-14       Impact factor: 41.582

View more
  10 in total

1.  UHRF2 promotes Hepatocellular Carcinoma Progression by Upregulating ErbB3/Ras/Raf Signaling Pathway.

Authors:  Jingjie Sun; Kejia Wu; Siyuan Chen; Shiming Jiang; Yong Chen; Changzhu Duan
Journal:  Int J Med Sci       Date:  2021-06-26       Impact factor: 3.738

2.  UHRF2 regulates cell cycle, epigenetics and gene expression to control the timing of retinal progenitor and ganglion cell differentiation.

Authors:  Xiaohong Wang; Aaron L Sarver; Qiyuan Han; Christopher L Seiler; Chencheng Xie; Huarui Lu; Colleen L Forster; Natalia Y Tretyakova; Timothy C Hallstrom
Journal:  Development       Date:  2022-03-14       Impact factor: 6.862

3.  Quantitative proteomics profiling reveals activation of mTOR pathway in trastuzumab resistance.

Authors:  Wenhu Liu; Jinxia Chang; Mingwei Liu; Jiangbei Yuan; Jinqiang Zhang; Jun Qin; Xuefeng Xia; Yi Wang
Journal:  Oncotarget       Date:  2017-07-11

4.  Loss of UHRF2 expression is associated with human neoplasia, promoter hypermethylation, decreased 5-hydroxymethylcytosine, and high proliferative activity.

Authors:  Huarui Lu; Sweta Bhoopatiraju; Hongbo Wang; Nolan P Schmitz; Xiaohong Wang; Matthew J Freeman; Colleen L Forster; Michael R Verneris; Michael A Linden; Timothy C Hallstrom
Journal:  Oncotarget       Date:  2016-11-15

5.  Overexpression of UHRF2 in intrahepatic cholangiocarcinoma and its clinical significance.

Authors:  Rui Peng; Xiaoyong Huang; Chi Zhang; Xuan Yang; Yaping Xu; Dousheng Bai
Journal:  Onco Targets Ther       Date:  2017-12-11       Impact factor: 4.147

6.  Label-Free Quantitative Proteomics Combined with Biological Validation Reveals Activation of Wnt/β-Catenin Pathway Contributing to Trastuzumab Resistance in Gastric Cancer.

Authors:  Wenhu Liu; Jiangbei Yuan; Zhenzhong Liu; Jianwu Zhang; Jinxia Chang
Journal:  Int J Mol Sci       Date:  2018-07-06       Impact factor: 5.923

7.  Shigellaflexneri Regulator SlyA Controls Bacterial Acid Resistance by Directly Activating the Glutamate Decarboxylation System.

Authors:  Buyu Zhang; Longhao Ran; Mei Wu; Zezhou Li; Jiezhang Jiang; Zhen Wang; Sen Cheng; Jiaqi Fu; Xiaoyun Liu
Journal:  Front Microbiol       Date:  2018-08-31       Impact factor: 5.640

8.  Recurrent chromosomal and epigenetic alterations in oral squamous cell carcinoma and its putative premalignant condition oral lichen planus.

Authors:  Christopher G Németh; Christoph Röcken; Reiner Siebert; Jörg Wiltfang; Ole Ammerpohl; Volker Gassling
Journal:  PLoS One       Date:  2019-04-09       Impact factor: 3.240

Review 9.  High-throughput proteomics: a methodological mini-review.

Authors:  Miao Cui; Chao Cheng; Lanjing Zhang
Journal:  Lab Invest       Date:  2022-08-03       Impact factor: 5.502

Review 10.  Proteomic Technology "Lens" for Epithelial-Mesenchymal Transition Process Identification in Oncology.

Authors:  Monica Neagu; Carolina Constantin; Marinela Bostan; Constantin Caruntu; Simona Rebeca Ignat; Sorina Dinescu; Marieta Costache
Journal:  Anal Cell Pathol (Amst)       Date:  2019-10-29       Impact factor: 2.916

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.